 Erik Schadde
Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 38 | 2021 | 65 | 12.280 |
Why?
| | Liver Neoplasms | 29 | 2021 | 117 | 10.180 |
Why?
| | Portal Vein | 28 | 2021 | 47 | 9.540 |
Why?
| | Liver | 19 | 2021 | 214 | 6.510 |
Why?
| | Liver Regeneration | 16 | 2020 | 27 | 5.570 |
Why?
| | Colorectal Neoplasms | 13 | 2021 | 125 | 3.890 |
Why?
| | Ligation | 21 | 2020 | 37 | 2.680 |
Why?
| | Embolization, Therapeutic | 6 | 2021 | 80 | 2.530 |
Why?
| | Laparoscopy | 6 | 2021 | 190 | 1.910 |
Why?
| | Hepatic Stellate Cells | 2 | 2020 | 11 | 1.520 |
Why?
| | Liver Diseases | 2 | 2018 | 40 | 1.320 |
Why?
| | Postoperative Complications | 12 | 2021 | 1083 | 1.230 |
Why?
| | Cause of Death | 3 | 2017 | 78 | 1.230 |
Why?
| | Registries | 9 | 2019 | 214 | 1.180 |
Why?
| | Liver Failure | 4 | 2019 | 14 | 1.100 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2021 | 41 | 1.040 |
Why?
| | Humans | 52 | 2021 | 31481 | 0.950 |
Why?
| | Treatment Outcome | 20 | 2021 | 3910 | 0.940 |
Why?
| | Hypertrophy | 4 | 2017 | 20 | 0.880 |
Why?
| | Organ Size | 9 | 2019 | 122 | 0.870 |
Why?
| | Sarcopenia | 1 | 2021 | 34 | 0.840 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 70 | 0.780 |
Why?
| | Retrospective Studies | 16 | 2021 | 3591 | 0.770 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 68 | 0.770 |
Why?
| | Male | 36 | 2021 | 17583 | 0.750 |
Why?
| | Kidney Transplantation | 5 | 2021 | 141 | 0.750 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 11 | 0.740 |
Why?
| | Hepatomegaly | 1 | 2018 | 6 | 0.730 |
Why?
| | Reperfusion Injury | 1 | 2018 | 9 | 0.730 |
Why?
| | Neuroendocrine Tumors | 5 | 2019 | 48 | 0.720 |
Why?
| | Publication Bias | 1 | 2018 | 8 | 0.710 |
Why?
| | Bibliometrics | 1 | 2018 | 22 | 0.690 |
Why?
| | Antioxidants | 1 | 2018 | 70 | 0.690 |
Why?
| | Reactive Oxygen Species | 1 | 2018 | 133 | 0.680 |
Why?
| | Oxidative Stress | 1 | 2018 | 140 | 0.680 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 389 | 0.660 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 29 | 0.660 |
Why?
| | Middle Aged | 26 | 2019 | 11209 | 0.650 |
Why?
| | Female | 31 | 2021 | 18253 | 0.620 |
Why?
| | Therapies, Investigational | 1 | 2016 | 6 | 0.610 |
Why?
| | Length of Stay | 5 | 2021 | 377 | 0.600 |
Why?
| | Aged | 20 | 2019 | 10295 | 0.560 |
Why?
| | Graft Rejection | 4 | 2008 | 84 | 0.520 |
Why?
| | Catheter Ablation | 1 | 2015 | 76 | 0.520 |
Why?
| | Liver Transplantation | 3 | 2015 | 114 | 0.490 |
Why?
| | Animals | 8 | 2021 | 5312 | 0.480 |
Why?
| | Blood Loss, Surgical | 3 | 2019 | 71 | 0.480 |
Why?
| | Prognosis | 8 | 2020 | 1028 | 0.450 |
Why?
| | Risk Factors | 10 | 2019 | 2664 | 0.450 |
Why?
| | Time Factors | 9 | 2019 | 1902 | 0.440 |
Why?
| | Feasibility Studies | 4 | 2016 | 281 | 0.430 |
Why?
| | Hepatic Veins | 3 | 2020 | 9 | 0.430 |
Why?
| | Operative Time | 4 | 2019 | 97 | 0.410 |
Why?
| | Survival Rate | 6 | 2018 | 465 | 0.400 |
Why?
| | Follow-Up Studies | 7 | 2018 | 2028 | 0.380 |
Why?
| | Models, Animal | 3 | 2020 | 149 | 0.380 |
Why?
| | Tissue Donors | 2 | 2021 | 79 | 0.380 |
Why?
| | Random Allocation | 3 | 2018 | 164 | 0.380 |
Why?
| | Isoantibodies | 2 | 2006 | 11 | 0.370 |
Why?
| | Neoplasm Staging | 5 | 2018 | 481 | 0.370 |
Why?
| | Intestinal Neoplasms | 2 | 2018 | 13 | 0.360 |
Why?
| | Antibodies, Neoplasm | 1 | 2008 | 15 | 0.350 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 181 | 0.350 |
Why?
| | Stomach Neoplasms | 2 | 2018 | 40 | 0.350 |
Why?
| | Pancreas Transplantation | 2 | 2021 | 16 | 0.340 |
Why?
| | Death | 1 | 2008 | 45 | 0.340 |
Why?
| | Swine | 2 | 2018 | 117 | 0.340 |
Why?
| | Rats, Wistar | 2 | 2017 | 64 | 0.320 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 56 | 0.320 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 163 | 0.320 |
Why?
| | Patient Selection | 4 | 2018 | 264 | 0.310 |
Why?
| | Switzerland | 3 | 2021 | 9 | 0.310 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 301 | 0.310 |
Why?
| | Adult | 15 | 2019 | 9779 | 0.300 |
Why?
| | Plasmapheresis | 1 | 2006 | 17 | 0.300 |
Why?
| | HLA Antigens | 1 | 2006 | 20 | 0.300 |
Why?
| | Antibody Formation | 1 | 2006 | 33 | 0.300 |
Why?
| | Rats | 2 | 2020 | 966 | 0.290 |
Why?
| | Risk Assessment | 5 | 2019 | 806 | 0.280 |
Why?
| | Philosophy, Medical | 1 | 2004 | 3 | 0.280 |
Why?
| | Spirituality | 1 | 2004 | 64 | 0.260 |
Why?
| | Ultrasonography | 3 | 2021 | 210 | 0.240 |
Why?
| | Tissue and Organ Procurement | 3 | 2012 | 37 | 0.230 |
Why?
| | Multivariate Analysis | 4 | 2019 | 390 | 0.230 |
Why?
| | Cell Proliferation | 2 | 2020 | 232 | 0.220 |
Why?
| | Organ Transplantation | 1 | 2021 | 43 | 0.220 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 55 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 31 | 0.220 |
Why?
| | Databases, Factual | 3 | 2019 | 391 | 0.220 |
Why?
| | Hospitals | 1 | 2021 | 142 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2019 | 1240 | 0.210 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 4 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 136 | 0.200 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 274 | 0.200 |
Why?
| | Adrenalectomy | 1 | 2019 | 6 | 0.200 |
Why?
| | Brazil | 2 | 2016 | 37 | 0.190 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2019 | 13 | 0.190 |
Why?
| | Disease Susceptibility | 1 | 2020 | 80 | 0.190 |
Why?
| | Adrenocortical Carcinoma | 1 | 2019 | 12 | 0.190 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 109 | 0.190 |
Why?
| | Conversion to Open Surgery | 1 | 2019 | 4 | 0.190 |
Why?
| | Abdominal Neoplasms | 1 | 2019 | 13 | 0.180 |
Why?
| | Liver Function Tests | 4 | 2017 | 33 | 0.180 |
Why?
| | Preoperative Period | 1 | 2019 | 73 | 0.180 |
Why?
| | Gallium Radioisotopes | 1 | 2018 | 3 | 0.180 |
Why?
| | bcl-2-Associated X Protein | 1 | 2018 | 13 | 0.180 |
Why?
| | Cytoprotection | 1 | 2018 | 11 | 0.180 |
Why?
| | Culture Media, Conditioned | 1 | 2018 | 33 | 0.180 |
Why?
| | Paracrine Communication | 1 | 2018 | 8 | 0.180 |
Why?
| | Organometallic Compounds | 1 | 2018 | 23 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 32 | 0.180 |
Why?
| | Hepatocytes | 1 | 2018 | 13 | 0.180 |
Why?
| | Hospital Mortality | 3 | 2015 | 192 | 0.180 |
Why?
| | Anesthesia | 1 | 2018 | 29 | 0.180 |
Why?
| | Digestive System Surgical Procedures | 1 | 2018 | 27 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 57 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2019 | 51 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 53 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2018 | 56 | 0.170 |
Why?
| | Portal Pressure | 1 | 2017 | 5 | 0.170 |
Why?
| | Liver Circulation | 1 | 2017 | 6 | 0.170 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 290 | 0.170 |
Why?
| | Logistic Models | 3 | 2016 | 479 | 0.170 |
Why?
| | Survival Analysis | 2 | 2017 | 379 | 0.160 |
Why?
| | Models, Biological | 1 | 2020 | 428 | 0.160 |
Why?
| | Hyperplasia | 1 | 2017 | 26 | 0.160 |
Why?
| | Fatty Liver | 1 | 2017 | 40 | 0.160 |
Why?
| | Melanoma | 1 | 2017 | 63 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 891 | 0.160 |
Why?
| | Apoptosis | 1 | 2018 | 292 | 0.160 |
Why?
| | Cell Hypoxia | 1 | 2016 | 17 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 375 | 0.150 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 8 | 0.150 |
Why?
| | Bile Duct Neoplasms | 1 | 2016 | 10 | 0.150 |
Why?
| | Reproducibility of Results | 1 | 2019 | 886 | 0.150 |
Why?
| | Primary Graft Dysfunction | 1 | 2015 | 3 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2017 | 237 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 207 | 0.150 |
Why?
| | Methyl Ethers | 1 | 2015 | 8 | 0.150 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 11 | 0.150 |
Why?
| | Anesthetics, Inhalation | 1 | 2015 | 12 | 0.150 |
Why?
| | Propofol | 1 | 2015 | 18 | 0.140 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 40 | 0.140 |
Why?
| | Signal Transduction | 1 | 2018 | 588 | 0.140 |
Why?
| | Obesity | 1 | 2018 | 338 | 0.140 |
Why?
| | Cohort Studies | 3 | 2017 | 2014 | 0.140 |
Why?
| | Safety | 1 | 2014 | 59 | 0.140 |
Why?
| | Disease Models, Animal | 1 | 2018 | 832 | 0.140 |
Why?
| | Surgeons | 1 | 2016 | 84 | 0.140 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 104 | 0.130 |
Why?
| | Viscera | 1 | 2013 | 2 | 0.130 |
Why?
| | Vascular Patency | 1 | 2013 | 31 | 0.130 |
Why?
| | Renal Artery | 1 | 2013 | 10 | 0.130 |
Why?
| | Aneurysm | 1 | 2013 | 20 | 0.120 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 27 | 0.120 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2013 | 44 | 0.120 |
Why?
| | Blood Transfusion | 1 | 2012 | 68 | 0.120 |
Why?
| | Endovascular Procedures | 1 | 2013 | 79 | 0.120 |
Why?
| | Bilirubin | 2 | 2016 | 14 | 0.110 |
Why?
| | Resource Allocation | 1 | 2011 | 5 | 0.110 |
Why?
| | Health Care Rationing | 1 | 2011 | 8 | 0.110 |
Why?
| | Linear Models | 1 | 2012 | 276 | 0.110 |
Why?
| | End Stage Liver Disease | 1 | 2011 | 17 | 0.110 |
Why?
| | Stents | 1 | 2013 | 155 | 0.110 |
Why?
| | Liver Cirrhosis | 2 | 2012 | 60 | 0.100 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 6 | 0.100 |
Why?
| | HLA-C Antigens | 1 | 2009 | 9 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2008 | 7 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 1 | 2008 | 11 | 0.090 |
Why?
| | Disease-Free Survival | 2 | 2019 | 241 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.090 |
Why?
| | Blood Vessels | 1 | 2007 | 19 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2008 | 55 | 0.090 |
Why?
| | Graft Survival | 1 | 2008 | 111 | 0.080 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 77 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 176 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2007 | 50 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2008 | 84 | 0.080 |
Why?
| | Incidence | 2 | 2021 | 829 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 136 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 179 | 0.080 |
Why?
| | HLA-DP Antigens | 1 | 2006 | 1 | 0.080 |
Why?
| | Complement C4b | 1 | 2006 | 3 | 0.080 |
Why?
| | Body Mass Index | 2 | 2018 | 458 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2006 | 122 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2017 | 5234 | 0.070 |
Why?
| | Religion and Medicine | 1 | 2004 | 24 | 0.070 |
Why?
| | Prospective Studies | 2 | 2021 | 1934 | 0.070 |
Why?
| | Hospitals, University | 2 | 2018 | 46 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 1273 | 0.060 |
Why?
| | Naphthoquinones | 1 | 2021 | 6 | 0.060 |
Why?
| | Benzofurans | 1 | 2021 | 8 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2021 | 40 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2021 | 19 | 0.050 |
Why?
| | Pancreas | 1 | 2021 | 36 | 0.050 |
Why?
| | Cold Ischemia | 2 | 2011 | 3 | 0.050 |
Why?
| | Sulfonamides | 1 | 2021 | 64 | 0.050 |
Why?
| | Mice | 2 | 2021 | 1894 | 0.050 |
Why?
| | Contrast Media | 1 | 2021 | 144 | 0.050 |
Why?
| | Mitotane | 1 | 2019 | 3 | 0.050 |
Why?
| | Kidney | 1 | 2021 | 210 | 0.050 |
Why?
| | Preoperative Care | 1 | 2020 | 146 | 0.050 |
Why?
| | Argentina | 1 | 2019 | 1 | 0.050 |
Why?
| | Blood Coagulation Disorders | 1 | 2019 | 15 | 0.050 |
Why?
| | Digestive System Neoplasms | 1 | 2018 | 6 | 0.050 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2018 | 17 | 0.050 |
Why?
| | Serum Albumin | 1 | 2019 | 28 | 0.050 |
Why?
| | Thymus Neoplasms | 1 | 2018 | 14 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2018 | 7 | 0.050 |
Why?
| | Europe | 1 | 2019 | 88 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 456 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 129 | 0.040 |
Why?
| | United States | 2 | 2018 | 2539 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2017 | 58 | 0.040 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2017 | 30 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2017 | 42 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 295 | 0.040 |
Why?
| | Anticoagulants | 1 | 2019 | 151 | 0.040 |
Why?
| | Edema | 1 | 2017 | 40 | 0.040 |
Why?
| | Treatment Failure | 1 | 2017 | 187 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 405 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 117 | 0.040 |
Why?
| | Italy | 1 | 2016 | 16 | 0.040 |
Why?
| | Medical Audit | 1 | 2016 | 8 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2017 | 82 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 10 | 0.040 |
Why?
| | Rabbits | 1 | 2017 | 326 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 236 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2016 | 77 | 0.040 |
Why?
| | Belgium | 1 | 2015 | 3 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2017 | 494 | 0.040 |
Why?
| | Age Factors | 1 | 2018 | 943 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2015 | 20 | 0.040 |
Why?
| | Sarcoma | 1 | 2017 | 139 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2016 | 82 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 390 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 327 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 637 | 0.030 |
Why?
| | Graft Occlusion, Vascular | 1 | 2013 | 29 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2017 | 442 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 687 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2018 | 756 | 0.030 |
Why?
| | Waiting Lists | 1 | 2011 | 18 | 0.030 |
Why?
| | Health Status Indicators | 1 | 2012 | 82 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2011 | 79 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2009 | 16 | 0.020 |
Why?
| | Immunization | 1 | 2009 | 50 | 0.020 |
Why?
| | Algorithms | 1 | 2012 | 412 | 0.020 |
Why?
| | Receptors, CXCR3 | 1 | 2007 | 2 | 0.020 |
Why?
| | Histocompatibility | 1 | 2007 | 5 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 30 | 0.020 |
Why?
| | Child | 1 | 2012 | 1572 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 292 | 0.020 |
Why?
| | Wisconsin | 1 | 2006 | 6 | 0.020 |
Why?
| | Kidney Tubules | 1 | 2006 | 15 | 0.020 |
Why?
| | Atrophy | 1 | 2006 | 108 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2006 | 96 | 0.020 |
Why?
|
|
Schadde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|